Preparation and Identification of Polyclonal Antibody Against CD47 Derived from Camel

doi:10.13560/j.cnki.biotech.bull.1985.2015.08.029

Abstract

Abstract: This work aims to verify whether or not recombinant human CD47 would induce high antibody response in Xinjiang Camelus bactrianus, and provide the experimental evidences for preparing anti-CD47 nanobody of high affinity. The gene segment of CD47 extracellular region was amplified by PCR and ligated into pET30a plasmid, and a prokaryotic expression vector was constructed. The recombinant CD47 protein (rCD4) was expressed by IPTG induction and purified with Ni-affinity chromatography. A male C. bactrian camel was immunized with purified rCD47 antigen. The enzyme-linked immunosorbent (ELISA) and Western blotting were applied to assay the titer of polyclonal antibody and the specific binding to CD47 protein. The purified rCD47 of high purity (90%) from prokaryotic expression vector of CD47 extracellular region bound specifically with B6H12.2 of anti-CD47. The ELISA results revealed that the titer of polyclonal anti-CD47 antibody in camel at least reached 1:200000 after the 7th immunization. The Western blotting results demonstrated that camel antiserum of resisting CD47 specifically bound with rCD47, and CD47 on membrane of Jurkat and Raji cells. In conclusion, the anti-CD47 polyclonal antibodies of high titer were raised in camel and it lay a promising foundation for the future experiment.

Key words: CCD47, polyclonal antibody, Bactrian camel, nanobody

Jia Erke, Feng Yaning, Li Jiangwei. Preparation and Identification of Polyclonal Antibody Against CD47 Derived from Camel[J]. Biotechnology Bulletin, 2015, 31(8): 200-205.

References

[1] Chao MP, Weissman IL, Majeti R. The CD47-SIRPα pathway in can-cer immune evasion and potential therapeutic implications[J]. Curr Opin Immunol, 2012, 24（2）：225-232.
[2] Brown EJ, Frazier WA. Integrin-associated protein（CD47）and its ligands[J]. Trends Cell Biol, 2001, 11（3）：130-1355.
[3] Jaiswal S, Jamieson CH, Pang WW, et al. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis[J]. Cell, 2009, 138：271-285.
[4] Sarfati M, Fortin G, Raymond M, et al. CD47 in the immune response：Role of thrombospondin and sirp-alpha reverse signaling[J]. Curr Drug Targets, 2008, 9（10）：842-850.
[5] Poels LG, Peters D, van MY, et al. Monoclonal antibody against human ovarian tumor associated antigens[J]. J Natl Cancer Inst, 1986, 76：781-791.
[6] Chao MP, Alizadeh AA, Tang C, et al. Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia[J]. Cancer Res, 2011, 71：1374-1384.
[7] Chao MP, Alizadeh AA, Tang C, et al. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma[J]. Cell, 2010, 142：699-713.
[8] Rendtlew Danielsen JM, Knudsen LM, Dahl IM, et al. Dysregulation of CD47 and the ligands thrombospondin 1 and 2 in multiple myeloma[J]. Br J Haematol, 2007, 138：756-760.
[9] Chan KS, Espinosa I, Chao MP, et al. Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells[J]. Proc Natl Acad Sci, 2009, 106：14016-14021.
[10] Willingham SB, Volkmer JP, Gentles AJ. The CD47-signal regulatory protein alpha（SIRPa）interaction is a therapeutic target for human solid tumors[J]. Proc Natl Acad Sci, 2012, 109（17）：6662-6667.
[11] Hamers-Casterman C, Atarhouch T, Muyldermans S, et al. Naturally occurring antibodies devoid of light chains[J]. Nature, 1993, 363（6428）：446-448.
[12] Serge M. Nanobodies：Natural single-domain antibodies[J]. Annual Review of Biochemistry, 2013, 82：17.1-17.23
[13] De GE, Silence K, Decanniere K, et al. Molecular basis for the preferential cleft recognition by dromedary heavy- chain antibodies[J]. Proc Natl Acad Sci USA, 2006, 103（12）：4586-4591.
[14] Zhao XW, Taco WK, Timo KB. targeting of CD47-SIRP? Enough for treating hematopoietic malignancy[J]. BLOOD, 2012, 119：18.
[15] Daley LP, Gagliardo LF, Duffy MS, et al. Application of monoclonal antibodies in functional and comparative investigations of heavy-chain immunoglobulins in new world camelids[J]. Clin Diagn Lab Immunol, 2005, 12（3）：380-386.
[16] Barclay AN, Van den Berg TK. The interaction between Signal Regulatory Protein Alpha（SIRPα）and CD47 structure, function, and therapeutic target[J]. Annu Rev Immunol, 2013, 32：25-50.
[17] Lauwereys M, Ghahroudi MA, Desmyter A, et al. Potent enzyme inhibitors derived from dromedary heavychain antibodies[J]. EMBO J, 1998, 17：3512-3520.